This is an interesting point.
Maybe they are challenging the appropriateness? If they win that argument then approval would be given based on trial results, unless they dig their heels in on one of the other tabled objections.
MSB has recently spent US$10M on this 'sticking point'.
It might well be a two pronged approach. Miss with the jab, then throw in an uppercut.
Ann: Appendix 4C Quarterly Activity Report, page-86
-
- There are more pages in this discussion • 88 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
97.0¢ |
Change
-0.025(2.51%) |
Mkt cap ! $1.107B | |||
| Open | High | Low | Value | Volume |
| 99.0¢ | $1.03 | 97.0¢ | $2.815M | 2.838M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 151781 | 97.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.5¢ | 80522 | 1 |
View Market Depth
| Last trade - 16.10pm 05/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |